The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Abstract
Tumor-associated neoangiogenesis has recently become a suitable target for antineoplastic drug development. In this overview, we discuss specific drug-associated hemostatic complications, the already known pathogenetic mechanisms involved, and the effect of varying antithrombotic strategies. Multiple agents with angiogenic inhibitory capacity (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus) have obtained US Food and Drug Administration approval, and many others have entered clinical trials. Arterial and venous thromboembolism and hemorrhage have emerged as significant toxicities associated with the use of angiogenesis inhibitors. We present a detailed analysis of the literature on thrombotic complication of antiangiogenic drugs. Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
Blom, J. W. (2005) · JAMA · doi:10.1001/jama.293.6.715 · Cited by 1,949
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Kabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Wells, P. G., McCallum, G. P., Chen, C. S., Henderson, J. T., Lee, C. J. J., Perstin, J., Preston, T. J., Wiley, M. J., & Wong, A. W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfn263 · Cited by 430
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer
Kotzsch, M., Farthmann, J., Meye, A., Fuessel, S., Baretton, G., Tjan-Heijnen, V. C. G., Schmitt, M., Luther, T., Sweep, F. C. G. J., Magdolen, V., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.002 · Cited by 50
Cited by
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Agnelli, G., George, D. J., Kakkar, A. K., Fisher, W., Lassen, M. R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F., & Turpie, A. G. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108898 · Cited by 531
Walker, A. J., Card, T. R., West, J., Crooks, C., & Grainge, M. J. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.021 · Cited by 512
Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment
Shovlin, C. L. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.07.001 · Cited by 502
Rak, J. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1267043 · Cited by 301
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Metadata
- Authors
- Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-10-10
- Volume
- 27
- Issue
- 29
- Pages
- 4865-4873
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2035056966
- Cited by
- 194
- References
- 10
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents. https://app.cochat.ai/papers/10.1200/jco.2009.22.3875
- The paper
- Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. (2009). Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.22.3875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
